Alpha 2.0
Login Register
» Authors » Scott Guenthner

Scott Guenthner

Explore the profile of Scott Guenthner including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 15
Citations 142
Followers 0
Related Specialties
Dermatology
General Medicine
Radiology
Top 10 Co-Authors
Steven Kempers
Kimmie Eads
Jessica Raiz
Christopher G Bunick
Kalyani Marathe
Joyce M C Teng
Dedee F Murrell
Leslie Castelo-Soccio
Alan M Mendelsohn
Kim A Papp
Published In
J Drugs Dermatol
J Am Acad Dermatol
Am J Clin Dermatol
Dermatol Ther (Heidelb)
Clin Exp Dermatol
Affiliations
Soon will be listed here.
Recent Articles
1.
Topical Isotretinoin (TMB-001) Treatment for 12 Weeks Did Not Result in Clinically Relevant Laboratory Abnormalities in Participants with Congenital Ichthyosis in the Phase 2b CONTROL Study
Marathe K, Teng J, Guenthner S, Bunick C, Kempers S, Eads K, et al.
Dermatol Ther (Heidelb) . 2023 May; 13(6):1255-1264. PMID: 37170057
Introduction: Treatment with oral retinoids can be effective in patients with congenital ichthyosis (CI) but may be associated with clinically significant laboratory changes. In this Phase 2b CONTROL study analysis,...
2.
Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL study
Bunick C, Teng J, Guenthner S, Marathe K, Kempers S, Eads K, et al.
Clin Exp Dermatol . 2023 Mar; 48(7):765-769. PMID: 36928932
Background: Emollients and keratolytics are frequently used to manage symptoms of congenital ichthyosis (CI). Systemic retinoid treatment is complicated by teratogenicity and dose-limiting adverse effects. Objectives: This analysis from the...
3.
Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosis
Murrell D, Teng J, Guenthner S, Marathe K, Kempers S, Eads K, et al.
Clin Exp Dermatol . 2023 Feb; 48(6):623-630. PMID: 36794376
Background: In two severe congenital ichthyosis subtypes, autosomal recessive lamellar ichthyosis (ARCI-LI) and X-linked recessive ichthyosis (XLRI), cutaneous manifestations include widespread scaling. Approved topical treatment options are limited to emollients...
4.
The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study
Gooderham M, Kircik L, Zirwas M, Lee M, Kempers S, Draelos Z, et al.
J Drugs Dermatol . 2023 Feb; 22(2):139-147. PMID: 36745371
Background: Patients with atopic dermatitis (AD) need safe and effective topical treatments. Objective: To assess safety and efficacy of roflumilast cream in patients with mild to moderate AD. Methods: In...
5.
The CONTROL study: A randomized, double-blind vehicle-controlled phase 2b study of novel topical isotretinoin formulation demonstrates improvement in recessive X-linked and autosomal recessive lamellar congenital ichthyosis
Teng J, Bunick C, Guenthner S, Murrell D, Marathe K, Kempers S, et al.
J Am Acad Dermatol . 2022 Jul; 87(6):1455-1458. PMID: 35872261
No abstract available.
6.
Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry
Sekulic A, Yoo S, Kudchadkar R, Guillen J, Rogers G, Chang A, et al.
PLoS One . 2022 Jan; 17(1):e0262151. PMID: 35030185
Background: Limited information is available regarding real-world treatment patterns and their effectiveness and safety in patients with locally advanced basal cell carcinoma, including patients not typically represented in clinical trials....
7.
Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis
Lebwohl M, Gold L, Strober B, Papp K, Armstrong A, Bagel J, et al.
N Engl J Med . 2021 Dec; 385(24):2219-2229. PMID: 34879448
Background: Tapinarof cream is a topical aryl hydrocarbon receptor-modulating agent under investigation for the treatment of psoriasis. Tapinarof modulates the expression of interleukin-17 and the skin-barrier proteins filaggrin and loricrin....
8.
Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts
Guenthner S, McFalda W, Tate M, Eads K, Rieger J, Glover D, et al.
Am J Clin Dermatol . 2021 Sep; 22(6):867-875. PMID: 34515985
Background: External genital warts are caused by various subtypes of the human papilloma virus and spread through direct skin-to-skin contact. Approximately 1% of the US population have external genital warts....
9.
COVE-1: A Phase 2, Open-Label Study to Evaluate Efficacy and Safety and the Optimal Regimen of VP-102, a Proprietary Drug-Device Product Containing Topical Cantharidin (0.7% w/v) Under Occlusion for the Treatment of Common Warts
Guenthner S, McFalda W, Kwong P, Eads K, McCafferty M, Rieger J, et al.
Dermatol Ther (Heidelb) . 2021 Jul; 11(5):1623-1634. PMID: 34286459
Introduction: Verrucae vulgaris, or common warts, is a common skin condition for which there is no US Food and Drug Administration-approved treatment. Compounded cantharidin has been used to treat warts...
10.
Inter- and Intra-physician variation in quantifying actinic keratosis skin photodamage
Schmeusser B, Borchers C, Travers J, Borchers S, Trevino J, Rubin M, et al.
J Clin Investig Dermatol . 2020 Oct; 8(2). PMID: 33088904
We investigated the variations in physician evaluation of skin photodamage based on a published photodamage scale. Of interest is the utility of a 10-level scale ranging from none and mild...